View the full list of references supporting this article in European Pharmaceutical Review, Issue 02 2026.

References

1. Establishing Impurity Specifications for Antibiotics, Guidance for Industry, April 2026. [Internet] FDA. Available from: https://www.fda.gov/media/192017/download.

2. Guideline on Setting Specifications For Related Impurities In Antibiotics. EMA. 30 June 2012 EMA/CHMP/CVMP/QWP/199250/2009 corr Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP).

3. ICH Q3A(R2). Impurities in New Drug Substances. Current Step 4 version dated 25 October 2006.

4. ICH Q3B(R2). Impurities in New Drug Products. Current Step 4 version dated 02 June 2006.

5. ICH M7(R2). Assessment and Control of DNA Reactive (Mutagenic) Impurities In Pharmaceuticals To Limit Potential Carcinogenic Risk. Final version, Adopted on 3 April 2023.

6. Control of Nitrosamine Impurities in Human Drugs Guidance for Industry. September 2024 (revision 2). [Internet] FDA. Available from: https://www.fda.gov/media/141720/download.

7. Grant J, Le Saux N. Duration of Antibiotic Therapy For Common Infections. J Assoc Med Microbiol Infect Dis Can. 2021;6(3):181–197.

8. Harvey J, Fleetwood A, Ogilvie R, et al. Management of Organic Impurities In Small Molecule Medicinal Products: Deriving Safe Limits For Use In Early Development. Regul Toxicol Pharmacol. 2017:84:116-123.

9. Reflection Paper On The Qualification Of Non-Mutagenic Impurities. EMA. 19 January 2026 EMA/CHMP/4299/2026 Committee for Medicinal Products for Human Use (CHMP).

10. Marcon N, Rüdt M, Klein J, et al. Quantitation of Antibiotics In Fresh Fermentation Medium By Hydrophilic Interaction Chromatography Mass Spectrometry. Anal Bioanal Chem. 2025; 417: 1927–1934.